Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nektar Therapeutics - Common Stock
(NQ:
NKTR
)
73.18
-1.88 (-2.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nektar Therapeutics - Common Stock
< Previous
1
2
Next >
NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 18, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Deadline Approaching: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
March 18, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
March 17, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
March 17, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 17, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
March 17, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
March 16, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
March 16, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 14, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Law Offices of Howard G. Smith Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
March 13, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 13, 2026
From
Schall Law
Via
GlobeNewswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
March 12, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Nektar Therapeutics (NKTR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
March 12, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
March 12, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
March 11, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
March 10, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
March 10, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
March 10, 2026
From
Pomerantz LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 10, 2026
From
Schall Law
Via
GlobeNewswire
Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims
March 10, 2026
From
Grabar Law Office
Via
GlobeNewswire
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR
March 10, 2026
From
DJS Law Group
Via
Business Wire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 09, 2026
From
The Schall Law Firm
Via
Business Wire
Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights
March 09, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 06, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit
March 06, 2026
From
Robbins LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
January 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
December 30, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.